Ann: New CardioCel product for vascular repair, page-3

ADMEDUS TO LAUNCH CARDIOCEL® PRODUCT FOR VASCULAR REPAIR  CardioCel® product range now includes three products sizes  CardioCel to be used in vascular repairs Brisbane, Australia May 18th, 2015 Admedus Limited (ASX: AHZ) today announced that it would launch a new CardioCel® product into the US market in June 2015. The new product will be a 2cm X 8cm tissue patch for vascular repairs such as carotid endarterectomies. The new CardioCel product launch is part of the Company’s strategy to expand the use of CardioCel across a range of surgical applications. “The new CardioCel product is part of Admedus’ plan to build an ADAPT™ Tissue franchise, providing surgeons with a range of products for surgical repairs,” said Admedus CEO Mr Lee Rodne. In addition to the use of CardioCel for cardiac repairs and reconstructions, the Company also announced that CardioCel has been successfully used in 10 US cases of vascular repair, including carotid endarterectomies and femoral artery repairs. The use of CardioCel in vascular applications is within the current indication for the USA. The vascular repair market represents a significant potential market with an estimated 180,000 carotid endarterectomies performed each year in the USA. “The Admedus sales team continues to expand the number of centers using CardioCel and this new product size will help to support broader market adoption and momentum in our sales program, which we anticipate will support further revenue growth in the coming year and beyond,” said Mr Rodne CardioCel is currently used in 31 European and 35 US centers and over 70 centers globally. Over 1800 patients have been implanted with CardioCel. Follow us: Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus